Dr Reddy’s Laboratories Ltd, a global pharmaceutical company, has secured a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection, marking a significant milestone in the Canadian pharmaceutical market. With this approval, Dr Reddy’s becomes the first company to receive marketing authorization for a generic version of Semaglutide Injection in Canada, achieving this ahead of the regulator’s target review timeline.
The authorization includes multiple dosage formats, specifically 2 mg per pen (1.34 mg/mL) and 4 mg per pen (1.34 mg/mL), enabling broader treatment options for patients. The company has initiated launch preparations and is working toward making the therapy available across Canada in the near term.
This development strengthens Dr Reddy’s commitment to expanding access to high-quality and cost-effective treatments for patients living with diabetes. Semaglutide, a GLP-1 receptor agonist, plays a critical role in improving glycemic control and supporting long-term disease management. The introduction of a generic alternative is expected to improve affordability and accessibility for patients who rely on such therapies.
Company leadership highlighted that Canada remains a key market within its global strategy. The early approval underscores the organization’s focus on regulatory excellence, strong research and development capabilities, and efficient execution. The company also emphasized its ability to ensure consistent supply through its in-house development and manufacturing infrastructure.
The approval further strengthens Dr Reddy’s presence in regulated markets and enhances its portfolio in diabetes care, an area of increasing global importance. By expanding its offerings in this segment, the company continues to align with its mission of improving patient outcomes through accessible medicines.
Founded in 1984 and headquartered in Hyderabad, India, Dr Reddy’s Laboratories has built a strong global footprint across key markets including the United States, India, Europe, Russia & CIS countries, China, and Brazil. Its portfolio spans active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products, covering major therapeutic areas such as cardiovascular, oncology, gastrointestinal, dermatology, pain management, and diabetology.
